Form 4: Revance Therapeutics Director Disposes of Shares Following Merger Agreement

Director Jill Beraud disposed of shares in Revance Therapeutics following the completion of a merger with Crown Laboratories.

Summary

• Jill Beraud, a director of Revance Therapeutics, filed a Form 4 indicating changes in beneficial ownership.
• On February 4, 2025, Beraud disposed of 28,606 shares of common stock at a price of $3.65 per share.
• On February 6, 2025, Beraud disposed of 15,000 shares of common stock.
• These transactions occurred as a result of the merger agreement between Revance Therapeutics and Crown Laboratories, Inc.
• The merger involved a cash tender offer for all outstanding shares of Revance at $3.65 per share.
• Restricted stock awards held by non-employee board members were canceled and converted into the right to receive the per share price.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reports a procedural transaction following a merger agreement.

Future Outlook

The merger between Revance Therapeutics and Crown Laboratories has been completed.

Industry Context

This announcement reflects a completed merger, a common occurrence in the pharmaceutical and biotechnology industries as companies seek to expand their portfolios, gain access to new technologies, or achieve economies of scale.

Stakeholder Impact

• Shareholders have received $3.65 per share as part of the merger agreement.

Key Dates

Keywords

Form 4, Revance Therapeutics, Merger, Share Disposal, Beneficial Ownership, Crown Laboratories